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ABSTRACT
Background. The aim of this study was to investigate the
effectiveness of adjuvant hepatic arterial infusion pump
(HAIP) chemotherapy after complete resection or ablation
of recurrent colorectal liver metastases (CRLM).
Methods. A retrospective cohort study was conducted of
patients from two centers who were treated with resection
and/or ablation of recurrent CRLM only between 1992 and
2018. Overall survival (OS) and hepatic disease-free sur-
vival (hDFS) were estimated using the Kaplan–Meier
method. The Cox regression method was used to calculate
hazard ratios (HRs) with corresponding 95% confidence
intervals (CI).
Results. Of 374 eligible patients, 81 (22%) were treated
with adjuvant HAIP chemotherapy. The median follow-up
for survivors was 65 months (IQR 32–118 months).
Patients receiving adjuvant HAIP were more likely to have
multifocal disease and receive perioperative systemic
chemotherapy at time of resection for recurrence. A
median hDFS of 46 months (95% CI 29–81 months) was
found in patients treated with adjuvant HAIP compared
with 18 months (95% CI 15–26 months) in patients treated
with resection and/or ablation alone (p = 0.001). The
median OS and 5-year OS were 89 months (95% CI
52–126 months) and 66%, respectively, in patients treated
with adjuvant HAIP compared with 57 months (95% CI
47–67 months) and 47%, respectively, in patients treated
with resection and/or ablation only (p = 0.002). Adjuvant
HAIP was associated with superior hDFS (adjusted HR
0.599, 95% CI 0.38–0.93, p = 0.02) and OS (adjusted HR
0.59, 95% CI 0.38–0.92, p = 0.02) in multivariable
analysis.
Conclusion. Adjuvant HAIP chemotherapy after resection
and/or ablation of recurrent CRLM is associated with
superior hDFS and OS.
Repeat resection of colorectal liver metastases (CRLM)
is safe and feasible.1–6 Nearly half of all patients undergo
re-resection and/or ablation for intrahepatic recurrences
after initial resection of CRLM.2,7 Previous studies have
demonstrated favorable overall survival (OS) for highly
selected patients after repeat hepatectomy, with a 5-year
OS of almost 50%.8 Unfortunately, over 60% of patients
recur again, involving the liver in 65% of all patients.6,9
Most of these repeat recurrences occur within 2 years after
re-intervention.8 Effective perioperative systemic or
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locoregional treatments to reduce or avoid liver recurrence
are needed, especially in patients who have already
developed liver-only recurrence.
Adjuvant hepatic arterial infusion pump (HAIP)
chemotherapy improved hepatic disease-free survival
(hDFS) 2 years after CRLM resection in a phase III trial
from 60 to 90%.10,11 HAIP chemotherapy involves intra-
arterial chemotherapy with floxuridine using a surgically
implanted subcutaneous pump. The high first-pass effect of
floxuridine allows for a regionally confined high dose of
chemotherapy to the liver. The rationale of adjuvant HAIP
chemotherapy is that residual micrometastases in the liver
after resection can be eliminated with this regional therapy.
The aim of this study was to investigate the outcomes
following adjuvant HAIP chemotherapy after resection




Consecutive patients treated between January 1992 and
December 2018 at Memorial Sloan Kettering Cancer
Center (MSKCC) or between January 2000 and December
2016 at the Erasmus MC Cancer Institute (Erasmus MC)
were identified from prospectively maintained liver resec-
tion databases. Only patients with recurrent liver-only
disease after prior liver resection or ablation were consid-
ered for inclusion.
Patients with incomplete resection of the primary or
liver tumors were excluded, as were patients with extra-
hepatic disease present prior to or at the time or hepatic
recurrence. Patients treated with HAIP chemotherapy at
any other stage than adjuvant for recurrent CRLM were
excluded. Patients treated with stereotactic body radiation
therapy were also excluded.
Patients were discussed at a multidisciplinary meeting
where resection, percutaneous ablation, and open ablation
were considered to be curative-intent treatment options.
Ablation included both radiofrequency and microwave
ablation.
HAIP chemotherapy with floxuridine and concurrent
systemic chemotherapy was administered in a similar way
to that used after initial resection of CRLM.12 A maximum
of 6 cycles of adjuvant HAIP chemotherapy was admin-
istered, starting 4 weeks after surgery. Perioperative
systemic chemotherapy was defined as any chemotherapy
received within 6 months prior to or after CRLM resec-
tion. Systemic chemotherapy was offered prior to resection
in patients with borderline or upfront unresectable CRLM
at both centers. At MSKCC, patients with upfront
resectable CRLM also received preoperative and/or adju-
vant systemic chemotherapy. At Erasmus MC, only
patients with early recurrence (within 6 months of primary
tumor resection) typically received neoadjuvant systemic
chemotherapy. A comparative survival analysis was per-
formed to identify any differences between patients treated
with perioperative systemic chemotherapy in both centers.
Definitions
Clinicopathological data were retrieved from two
prospectively maintained databases. Primary tumors were
classified as right-sided if arising proximal to the splenic
flexure and left-sided if arising at or distal to the splenic
flexure. Primary tumors arising at the rectosigmoid junc-
tion or distally were considered rectal tumors. The total
number of CRLM was determined by the total number of
lesions present in the resected specimen as well the total
number of lesions ablated. The size of the largest tumor
was similarly derived from the pathology report. The dis-
ease-free interval was calculated from the time of primary
tumor resection to detection of the index CRLM. The
recurrence-free interval was defined as the time of resec-
tion of the index CRLM to time of detection of the
recurrent CRLM. The clinical risk score (CRS) was cal-
culated at initial presentation and used to stratify patients
into low risk (CRS 0–2) and high risk (CRS 3–5) of
recurrence of disease.13 The CRS is the sum of five poor
prognostic factors: node-positive primary colorectal tumor,
disease-free interval below 12 months, multifocal CRLM,
largest tumor greater than 5 cm, and serum carcinoem-
bryonic antigen (CEA) level above 200 lg/l.13
Follow-up
During follow-up at MSKCC after initial hepatectomy,
serum CEA measurements and radiological imaging (ab-
dominal and thoracic) were performed every 3–6 months
for the first 3 years, and yearly thereafter. At Erasmus MC,
follow-up was similar with radiological imaging every
3–6 months for the first 2 years, and yearly thereafter until
5 years.
Statistical Analysis
Overall survival (OS) was defined as the time from
curative treatment of liver recurrence to the time of death
or last follow-up, and hDFS was defined from the time of
resection and/or ablation of liver recurrence to the time of
subsequent liver recurrence, death, or last follow-up.
Continuous variables were expressed as medians with
interquartile range (IQR) and compared among groups
using the Mann–Whitney U test. Categorical variables
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were expressed as proportions and compared among groups
using the Chi square test. Kaplan–Meier methods were
used to estimate survival, and the log-rank test was used to
compare survival across groups. Univariable and multi-
variable Cox regression analyses were performed to
identify factors associated with survival. The total CRS,
rather than the individual factors of the CRS, was used in
the Cox regression analyses due to the limited number of
events per predictor variable. Factors with a p value of 0.20
and less were included in the multivariable model. Back-
ward selection with stepwise elimination of factors with a
p value of more than 0.20 was performed in multivariable
Cox regression analyses. A p value less than 0.05 was
considered statistically significant. Analyses were per-
formed using SPSS (IBM Corp, version 24, Armonk, NY)
and RStudio (RStudio, version 1.0.153, Boston, MA). The




During the study periods, 3299 patients underwent a
curative-intent treatment of CRLM at Memorial Sloan
Kettering Cancer Center (MSKCC, New York, United
States) and 1102 patients at Erasmus MC Cancer Institute
(Erasmus MC, Rotterdam, the Netherlands). A total of
4027 patients were excluded (Fig. 1). The most common
reasons for exclusion were perioperative HAIP treatment at
time of index CRLM resection (n = 975, 22.2%), no
recurrence noted in the study period (n = 935, 21.1%),
extrahepatic recurrence only (n = 565, 12.8%), and pres-
ence of both intra- and extrahepatic recurrences (n = 366,
8.3%). The final group comprised 374 patients, including
81 patients (21.7%) treated with adjuvant HAIP
chemotherapy at MSKCC. The majority of patients did not
receive HAIP chemotherapy (n = 293). These patients
FIG. 1 Study flowchart
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TABLE 1 Baseline characteristics
All patients No HAIP HAIP p value
Total 374 293 81 –
Patient characteristics
Gender 0.005
Male 235 195 (66.6%) 40 (49.4%)
Female 139 98 (33.4%) 41 (50.6%)
Center –
Erasmus MC 143 (38.8%) 143 (49.8%) –
MSKCC 231 (61.2%) 150 (51.2%) 81 (100%)
Colorectal cancer
Primary tumor location 0.24
Right-sided 78 (21.4%) 56 (19.6%) 22 (27.8%)
Left-sided 175 (48.1%) 138 (48.4%) 37 (46.8%)
Rectum 111 (30.5%) 91 (31.9%) 20 (25.3%)
Missing 10
Pathologic T-stage 0.09
T1–T2 57 (16.4%) 50 (18.1%) 7 (9.7%)
T3–T4 291 (83.6%) 226 (81.9%) 65 (90.3%)
Missing 26
Primary tumor node status 0.003
N0 146 (40.1%) 126 (44.1%) 20 (25.6%)
N? 218 (59.9%) 160 (55.9%) 58 (74.4%)
Missing 10
Index CRLM
Age at resection (median, IQR) 61 (53–69) 63 (56–70) 54 (46–63) \ 0.001
\ 70 years 295 (78.9%) 219 (74.7%) 76 (93.8%)
C 70 years 79 (21.1%) 74 (25.3%) 5 (6.2%)
Disease-free interval 0.14
B 12 months 77 (20.6%) 65 (22.3%) 12 (14.8%)
[ 12 months 296 (79.4%)
1
227(77.7%) 69 (85.2%)
Number of CRLM 0.48
1 150 (41.4%) 120 (42.4%) 30 (38.0%)
[ 1 212 (58.6%) 163 (57.6%) 49 (62.0%)
Missing 12
Size of largest CRLM 0.08
B 5 cm 296 (88.4%) 230 (86.6%) 66 (94.3%)
[ 5 cm 39 (11.6%) 35 (13.4%) 4 (5.7%)
Missing 39
Preoperative CEA 0.61
B 200 lg/l 281 (91.2%) 228 (90.8%) 53 (93.0%)
[ 200 lg/l 27 (8.8%) 23 (9.2%) 4 (7.0%)
Missing 66
Clinical risk score 0.09
Low risk (0–2) 184 (56.8%) 152 (59.1%) 32 (47.8%)
High risk (3–5) 140 (43.2%) 105 (40.9%) 35 (52.2%)
Missing 50
Positive resection margin 0.15
Yes 46 (12.8%) 38 (13.5%) 7 (9.2%)
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were equally distributed between MSKCC (n = 148) and
Erasmus MC (n = 145).
Patient characteristics are summarized in Tables 1 and
2. HAIP patients were younger. More patients treated with
HAIP chemotherapy had node positive primary tumors
(n = 58, 74.4%) compared with no HAIP patients
(n = 160, 55.9%; p = 0.003). The number of recurrent
CRLM was higher in HAIP patients (median 2 versus 1,
p\ 0.001). All patients treated with HAIP chemotherapy
(n = 81, 100%) received perioperative systemic
chemotherapy at time of recurrence compared with
approximately one-third of patients treated with no HAIP
(n = 108, 37.5%; p\ 0.001).
Survival Outcomes
Median follow-up for survivors was 65 months (95% CI
57–73 months), and 190 patients (50.8%) died during fol-
low-up. Duration of follow-up was similar between HAIP
patients (73 months, 95% CI 56–90) and no HAIP patients
(62 months, 95% CI 52–72). No differences were found for
OS (p = 0.65) in patients from either center that were
treated with perioperative systemic chemotherapy
TABLE 1 continued
All patients No HAIP HAIP p value
No 294 (81.9%) 231 (82.2%) 62 (81.6%)
RFA 19 (5.3%) 12 (4.3%) 7 (9.2%)
Missing 15
Ablation at time of resection 0.46
Yes 90 (24.1%) 73 (24.9%) 17 (21.0%)
No 284 (75.9%) 220 (75.1%) 64 (79.0%)
Perioperative SYS \ 0.001
Yes 277 (77.3%) 203 (69.3%) 74 (92.5%)
No 96 (25.7%) 90 (30.7%) 6 (7.5%)
Missing 1
CEA carcinoembryonic antigen, CRLM colorectal liver metastases, Erasmus MC Erasmus Medical Center, MSKCC Memorial Sloan Kettering
Cancer Center, SYS systemic chemotherapy
TABLE 2 Characteristics at
the time of recurrence
Recurrent CRLM All patients No HAIP HAIP p value
Total 374 293 81 –
Recurrence-free interval (median, IQR) 11.0 (7.0–19.3) 11.0 (7.0–20.0) 12.0 (7.0–17.0) 0.91
Number of CRLM (median, IQR) 1 (1–2) 1 (1–2) 2 (1–2) \ 0.001
Missing 16
Size of largest CRLM (median, IQR) 2.1 (1.5–3.0) 2.1 (1.5–3.1) 2.1 (1.6–2.1) 0.78
Missing 61
CEA at recurrence (median, IQR) 6.4 (3.0–15.2) 6.9 (3.0–16.4) 6.3 (2.9–13.3) 1.00
Missing 94
Treatment \ 0.001
Resection only 252 (67.4%) 175 (59.7%) 77 (95.1%)
Resection with ablation 22 (5.9%) 19 (6.5%) 1 (1.2%)
Ablation only 100 (26.7%) 99 (33.8%) 3 (3.7%)
Perioperative SYS \ 0.001
Yes 189 (51.2%) 108 (37.5%) 81 (100%)
No 180 (48.8%) 180 (62.5%)
Missing 2
CEA carcinoembryonic antigen, CRLM colorectal liver metastases, IQR interquartile range, SYS systemic
chemotherapy
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(Supplementary Figure 1). In addition, no differences were
found for OS (p = 0.59) in patients that were treated with
resection with/or without ablation versus ablation only.
Hepatic Disease-Free Survival
The median hDFS was 46 months (95% CI
29–81 months) for patients treated with HAIP chemother-
apy compared with 19 months (95% CI 15–26 months) for
patients treated without HAIP chemotherapy (p = 0.001,
Fig. 2). On univariable analysis, recurrence-free interval
(HR 0.99, 95% CI 0.98–1.00, p = 0.03), preoperative CEA
level at recurrence (HR 1.01, 95% CI 1.00–1.01, p = 0.01),
ablation only procedures (HR 1.80, 95% CI 1.37–2.37,
p\ 0.001), and HAIP chemotherapy treatment (HR 0.60,
95% CI 0.43–0.82, p = 0.001) were associated with hDFS
(Supplementary Table 1). On multivariable analysis, the
number of CRLM at the time of recurrence (adjusted HR
1.23, 95% CI 1.06–1.42, p = 0.006), ablation only proce-
dure (adjusted HR 1.56, 95% CI 1.09–2.24, p = 0.02), and
HAIP chemotherapy treatment (adjusted HR 0.59, 95% CI
0.38–0.93, p = 0.02) were the only independent prognostic
factors for hDFS.
Overall Survival
The median OS was 92 months (95% CI
64–120 months) for patients treated with HAIP
chemotherapy compared with 57 months (95% CI
47–67 months) for patients treated without HAIP
chemotherapy (p = 0.002, Fig. 3). The 5-year OS was 66%
in HAIP patients compared with 47% in no HAIP patients.
Prognostic factors associated with OS on univariable
analysis were positive resection margin at the time of index
CRLM resection (HR 1.79, 95% CI 1.17–2.27, p = 0.007),
elevated CEA level at recurrence (HR 1.01, 95% CI
1.00–1.01, p\ 0.001), and adjuvant HAIP chemotherapy
treatment (HR 0.56, 95% CI 0.38–0.82, p = 0.003,
Table 3). On multivariable analysis, the CEA level at the
time of recurrent CRLM detection (adjusted HR 1.01, 95%
CI 1.00–1.01, p = 0.004) and HAIP chemotherapy treat-
ment (adjusted HR 0.59, 95% CI 0.38–0.92, p = 0.02)
remained independent prognostic factors for OS.
DISCUSSION
This study found that patients receiving adjuvant HAIP
chemotherapy after resection and/or ablation of recurrent
CRLM had superior hDFS and OS. Patients who received
adjuvant HAIP chemotherapy were younger, had more
advanced disease, and were more likely to receive peri-
operative systemic chemotherapy. However, adjuvant
HAIP chemotherapy was an independent prognostic factor
in multivariable analysis for both hDFS (adjusted HR 0.51,
p = 0.002) and OS (adjusted HR: 0.59, p = 0.02).
In a previous study, we found that perioperative sys-
temic chemotherapy had no impact on the intrahepatic
recurrence rate after initial resection of CRLM.14 There-
fore, it seems unlikely that it would be beneficial in the
setting of liver-only recurrence. Adjuvant HAIP
chemotherapy has been shown to significantly decrease the
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FIG. 2 Kaplan-Meier analysis for hepatic disease-free survival
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FIG. 3 Kaplan-Meier analysis for overall survival
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initial resection of CRLM in randomized controlled tri-
als.10,15 Moreover, adjuvant HAIP was associated with
improved median OS from 44 months to 67 months in a
retrospective study with 2368 patients.16 Outcomes from
treatment of recurrent CRLM with adjuvant HAIP
chemotherapy have not been studied. The rationale for
adjuvant HAIP chemotherapy after resection and/or abla-
tion of recurrences confined to the liver is that these
patients have demonstrated a propensity for liver-confined
metastatic disease, which may explain the favorable results
of HAIP found in our study of these patients.
The safety and effectiveness of repeat hepatectomy in
selected patients have been reported in several studies.1–6
With proper selection, repeat hepatectomy is considered
safe, with similar mortality and morbidity to the initial
hepatectomy. In well-selected patients, median OS after
second hepatectomy has been reported to range from 32 to
43 months,2,6,8,17 and 5-year OS rates ranged from 30% to
48%.3,6,8 A systematic review and meta-analysis of 22
studies, including 1610 patients, found a median OS after
hepatectomy for recurrent disease of 35 months and a
5-year OS of 42%.6 Notably, the median OS of patients not
treated with adjuvant HAIP chemotherapy in our study was
57 months, and the 5-year OS was 47%. This superior
survival in our study, compared with historical cohorts,
may be attributable to the strict inclusion criteria of our
study, excluding patients with prior extrahepatic disease or
extrahepatic recurrence at the time of intrahepatic recur-
rence. Patients with extrahepatic disease were excluded
because a previous study found no benefit in OS of HAIP in
patients with extrahepatic disease.16
Previous studies identified factors associated with worse
OS to include CRLM larger than 5 cm at initial hepatec-
tomy, age below 40 years at initial hepatectomy, more than
5 liver tumors at repeat hepatectomy, and major hepatec-
tomy at time of repeat resection.1,5 A concern about
previous studies is their small sample size, limiting the
power of their analyses. None of these previously identified
prognostic factors at the time of initial hepatectomy was
associated with OS in multivariable analysis in our study.
In addition to the administration of HAIP chemotherapy,
we also found that CEA level (adjusted HR 1.01, 95% CI
1.00–1.01, p = 0.004) was independently associated with
OS. The number of CRLM at the time of recurrence (ad-
justed HR 1.23, 95% CI 1.06–1.42, p = 0.006), ablation
only procedures (adjusted HR 1.56, 95% CI 1.09–2.24,
p = 0.02), and HAIP chemotherapy treatment (adjusted HR
0.59, 95% CI 0.38–0.93, p = 0.02) were the only inde-
pendent prognostic factors for hDFS.
In the current study, patients treated with resection and/
or ablation were included. Two small studies compared
these approaches in patients with recurrent CRLM.4,8 The
first retrospective study evaluated 64 patients and found
similar OS in patients treated with resection (n = 31,
33 months) or open/percutaneous ablation (n = 33,
33 months; p = 0.45).4 Another retrospective study of 91
patients found similar results with a 5-year OS of 52% in
patients treated with resection compared with 53% in
patients treated with percutaneous ablation.8 A limiting
factor is the absence of pathological confirmation of
CRLM diagnosis after ablation-only procedures, which
comprised one-third (n = 99, 33.8%) of patients in the no
TABLE 3 Univariable and
multivariable Cox regression
analysis of factors associated
with overall survival
Univariable Multivariable
HR 95% CI p value HR 95% CI p value
Index CRLM resection
Age ([ 70 years) 1.27 0.89–1.81 0.19
Right-sided tumor 0.94 0.64–1.37 0.73
Pathologic T-stage (T3–T4) 0.97 0.64–1.47 0.89
Clinical risk score (High) 0.97 0.71–1.34 0.87
Resection margin (R1) 1.79 1.17–2.27 0.007 1.59 0.97–2.61 0.07
Recurrent CRLM resection
Recurrence-free interval* 0.99 0.98–1.00 0.11
Number of recurrent CRLM* 1.07 0.94–1.22 0.29
Diameter of recurrent CRLM* 1.01 0.91–1.12 0.86
CEA at recurrence* 1.01 1.00–1.01 \ 0.001 1.01 1.00–1.01 0.004
Ablation only procedure 1.26 0.90–1.76 0.18
Perioperative SYS 1.20 0.89–1.61 0.24
Adjuvant HAIP 0.56 0.38–0.82 0.003 0.59 0.38–0.92 0.02
SYS systemic chemotherapy, CEA carcinoembryonic antigen, CRLM colorectal liver metastases
*Continuous
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HAIP group in the current study. More patients in the no
HAIP group were treated with ablation only (34% versus
4%) at time of liver recurrence. However, similar OS was
found in patients treated with resection (with or without
ablation) or ablation only at time of liver recurrence
(p = 0.59). In addition, no difference was found in the
number of ablations in the no HAIP group (n = 73, 25%)
compared with the HAIP group (n = 17, 21%) (p = 0.46) at
time of initial CRLM treatment. No association of ablative
procedures without resection and OS (HR 1.26, 95% CI
0.90–1.76, p = 0.18) could be demonstrated.
In the present study, all patients receiving HAIP
chemotherapy were concomitantly treated with systemic
chemotherapy. Therefore, this study did not evaluate the
effectiveness of HAIP chemotherapy alone. Moreover,
different regimes were used over time due to the avail-
ability of newer chemotherapy regimens relatively
recently. Limited evidence is available on the value of
perioperative systemic chemotherapy in patients with
repeat hepatectomy.7 In our study, perioperative systemic
chemotherapy was not associated with survival in multi-
variable analysis (HR 1.20, p = 0.24).
A limitation of this study was the extensive period of
inclusion. During this period, the selection criteria for re-
resection likely changed as well as the available periop-
erative systemic chemotherapy agents.2 However, factors
such as number of CRLM, size of CRLM, and CEA level
were included in the multivariable analysis, adjusting for
this time effect. Moreover, systemic chemotherapy (re-
gardless of the regimen) was not associated with OS.
Another limitation of this study was the absence of geno-
mic data (KRAS and BRAF mutations). These genomic
alterations may have influenced survival. However, previ-
ous studies have demonstrated that the effect of HAIP
chemotherapy is independent of KRAS mutational stud-
ies.18 Other studies demonstrated that RAS mutations are
associated with unsalvageable recurrences after initial
hepatectomy; this may also apply for subsequent recur-
rences after curative treatment of recurrent CRLM.19
However, primary tumor location, which is associated with
KRAS mutations, and inferior survival in right-sided
patients in previous studies, were included in multivariable
analysis in this paper.20 The use of tumor location likley
makes up for the absence of KRAS mutational status in our
study. Furthermore, it has also been shown that BRAF
rarely presents with isolated and resectable disease, making
it unlikely that BRAF would have been a relevant factor for
these patients.21
In addition, it is unknown whether treatment of subse-
quent recurrences differed between the two centers. Since
all patients treated with adjuvant HAIP chemotherapy for
liver recurrence originated from MSKCC, any difference in
treatment of subsequent recurrences could have introduced
bias. Furthermore, HAIP chemotherapy was administered
at the discretion of the treating medical oncologists and
surgical oncologists. HAIP chemotherapy requires regular
outpatient clinic visits (every 2 weeks) for refill of the
pump; this is not possible for most patients living far away
from MSKCC. Relative contra-indications for HAIP
chemotherapy are patients with a completely replaced right
and left hepatic artery, patients with partial portal vein
thrombosis, and patients with extrahepatic disease.
This is the first study reporting on the effectiveness of
adjuvant HAIP chemotherapy in patients after resection
and/or ablation of recurrent CRLM. Our findings suggest
that a prospective trial is indicated to investigate the
favorable hDFS and OS of adjuvant HAIP after resection
and/or ablation of recurrent CRLM.
In conclusion, this retrospective study found that HAIP
is independently associated with superior hDFS and OS
after resection or ablation for isolated recurrent CRLM.
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